FPA 144

Drug Profile

FPA 144

Alternative Names: FPA144

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 May 2017 Five Prime Therapeutics plans a phase I trial for Gastric cancer in Japan
  • 04 May 2017 Five Prime Therapeutics plans a front-line therapy trial
  • 05 Jul 2016 FPA 144 receives Orphan Drug status for Gastric cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top